There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > BCMA


BCMA Molecule Information

Name:B-cell maturation protein
Target Synonym:Tumor necrosis factor receptor superfamily member 17;B-cell maturation protein;CD_antigen: CD269;BCMA;TNFRSF17;BCM
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:28
Lastest Research Phase:Phase ?

BCMA Protein Product ListCompare or Buy

BCMA Molecule Synonym Name


BCMA Molecule Background

Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) is also known as B-cell maturation protein (BCMA), CD antigen CD269, which is a member of the TNF-receptor superfamily. TNFRSF17 contains one TNFR-Cys repeat. TNFRSF17 is expressed in mature B-cells, but not in T-cells or monocytes. TNFRSF17 is receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. TNFRSF17 promotes B-cell survival and plays a role in the regulation of humoral immunity. TNFRSF17 can activate NF-kappa-B and JNK.

BCMA References

BCMA Related Molecule

BCMA Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) Phase Ⅰ The First Affiliated Hospital of Nanchang University Multiple myeloma (MM) Details
TNB-383B TNB-383B Phase Ⅰ Teneobio, Abbvie Multiple myeloma (MM) Details
LCAR-B38M cell product JNJ-4528; JNJ-68284528; LCAR-B38M, JNJ 4528 Phase Ⅲ Nanjing Chuanqi Biotech, Janssen Multiple myeloma (MM) Details
Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) Phase Ⅰ Wuhan Union Hospital, Shengyan Pharmaceutical Technology Multiple myeloma (MM) Details
BCMA-CART (PD-1 knockdown, Unicar-Therapy Bio-medicine Technology) IND Filing Unicar-Therapy Bio-medicine Technology Multiple myeloma (MM) Details
Belantamab mafodotin GSK-2857916 Phase Ⅲ GlaxoSmithKline Multiple myeloma (MM) Details
Idecabtagene vicleucel bb-2121 Phase Ⅲ bluebird bio, Celgene Multiple myeloma (MM) Details
BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) Phase Ⅱ General Hospital of the People's Liberation Army Multiple myeloma (MM) Details
CART-BCMA CART-BCMA; MTV-273,CART BCMA,MTV273 Phase Ⅰ University of Pennsylvania, Novartis Multiple myeloma (MM) Details
P-BCMA-101 P-BCMA-101 Phase Ⅱ Poseida Therapeutics Multiple myeloma (MM) Details
BCMA CAR-NK 92 cell therapy (Asclepius Technology Company Group) Phase Ⅱ Asclepius Technology Company Group Multiple myeloma (MM) Details
BCMA-CS1 cCAR T cell therapy (iCell Gene Therapeutics) Phase Ⅰ iCell Gene Therapeutics Multiple myeloma (MM) Details
Anti-BCMA CAR T-cell therapy (Arcellx) CART-ddBCMA Phase Ⅰ Arcellx Multiple myeloma (MM) Details
HPN-217 HPN-217 Phase Ⅱ Harpoon Therapeutics, Abbvie Multiple myeloma (MM) Details
CC-99712 CC-99712 Phase Ⅰ Celgene Multiple myeloma (MM) Details
Human BCMA chimeric antigen receptor autologous T cell(Nanjing Reindeer Medical Technology) CT103A Phase Ⅰ Innovent Biologics, Nanjing IASO Biotherapeutics Multiple myeloma (MM) Details
MEDI-2228 MEDI-2228,MEDI 2228,MEDI2228 Phase Ⅰ MedImmune Multiple myeloma (MM) Details
SEA-BCMA SEA-BCMA; SGN-BCMA Phase Ⅰ Seattle Genetics Multiple myeloma (MM) Details
PBCAR-269A PBCAR-269A Phase Ⅱ Precision BioSciences Multiple myeloma (MM) Details
Anti-BCMA CAR-T cell therapy (PersonGen Biomedicine) Phase Ⅰ PersonGen Biomedicine, Second Affiliated Hospital of Suzhou UniversitySecond Affiliated Hospital of Suzhou University Multiple myeloma (MM) Details
BCMA CAR-T Cells (Pregene) Phase Ⅰ Pregene Multiple myeloma (MM) Details
bb-21217 bb-21217,bb 21217,bb21217 Phase Ⅰ bluebird bio, Celgene Multiple myeloma (MM) Details
AMG-420 AMG-420; BI-836909 Phase Ⅰ Micromet, Boehringer Ingelheim, Amgen Multiple myeloma (MM) Details
KITE-585 KITE-585,KITE585 Phase Ⅰ Kite Pharma, National Cancer Institute Multiple myeloma (MM) Details
REGN-5459 REGN-5459 Phase Ⅰ Regeneron Pharmaceutical Multiple myeloma (MM) Details
PF-06863135 PF-06863135,PF 06863135 Phase Ⅰ Pfizer Multiple myeloma (MM) Details
BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics) Phase Ⅰ iCell Gene Therapeutics Multiple myeloma (MM), Lymphoma Details
LCAR-B4822M LCAR-B4822M,LCAR B4822M,LCARB4822M Phase Ⅰ GenScript Biotech Corporation Multiple myeloma (MM) Details
CAR-BCMA T cell therapy CT-053-CARsgen Phase Ⅰ CARsgen Therapeutics Multiple myeloma (MM) Details
Anti BCMA CAR T cell therapy (Shanghai Hrain Biotechnology) BCMA-CART Phase Ⅰ Shanghai Hrain Biotechnology Multiple myeloma (MM) Details
JNJ-64007957 JNJ-7957; JNJ-64007957; JNJ-64007959 Phase Ⅰ Janssen, Genmab Multiple myeloma (MM) Details
AUTO-2 AUTO-2; SUB-96123,AUTO 2; SUB 96123 Phase Ⅱ Autolus Multiple myeloma (MM) Details
CC-93269 CC-93269; EM-901 Phase Ⅰ Celgene Multiple myeloma (MM) Details
ACTR 087/SEA BCMA combination therapy Phase Ⅰ Unum Therapeutics, Seattle Genetics Multiple myeloma (MM) Details
anti-BCMA CAR T-cell Therapy (Juno Therapeutics) ET-140; ET140-CAR; JCARH-125; FCARH-143; MCARH-171 Phase Ⅱ Juno Therapeutics Acute lymphoblastic leukaemia (ALL), Non-Hodgkin B-cell lymphomas Details
ALLO-715 ALLO-715 Phase Ⅰ Allogene Therapeutics, Cellectis Multiple myeloma (MM) Details
BCBM CAR T cell (Pregene) Phase Not Specified Pregene, BioCast Multiple myeloma (MM) Details

This web search service is supported by Google Inc.